An engineered 4-1BBL fusion protein with "activity on demand"

Area of Science:

• Oncology
• Immunotherapy
• Protein Engineering

Background:

• Engineered cytokines are crucial in cancer therapy but often cause toxicity.
• 4-1BB (tumor necrosis factor receptor superfamily) is a therapeutic target.
• Current strategies involve agonistic antibodies or the 4-1BBL ligand.

Purpose of the Study:

• To engineer an antibody-cytokine fusion protein with conditional activity.
• To reduce systemic toxicity associated with cytokine-based therapies.
• To develop a targeted cancer treatment with "activity on demand" properties.

Main Methods:

• Engineering of the F8-4-1BBL antibody fusion protein.
• Assessment of cytokine activity in solution and on antigen binding.
• In vivo biodistribution studies to evaluate tumor localization.
• Evaluation of antitumor activity in mouse cancer models.

Main Results:

• F8-4-1BBL demonstrated antigen-specific binding to the EDA domain of fibronectin.
• Selective tumor localization was confirmed by biodistribution experiments.
• Potent antitumor activity was observed in various mouse cancer models.
• No apparent toxicity was detected at effective doses.

Conclusions:

• F8-4-1BBL functions as a prototype for "activity on demand" antibody-cytokine fusion proteins.
• Conditional activity at the disease site minimizes toxicity to normal tissues.
• This approach offers a promising strategy for safer and more effective cancer immunotherapy.